Voltage-gated sodium channel blockers for the treatment of chronic pain

Current Topics in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 362-376

  Matulenko, Mark A ^a   Scanio, Marc J C ^a   Kort, Michael E ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Blocker; Pain; Selective; Sodium channel; Voltage gated

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; AMITRIPTYLINE; ARYLIMIDAZOLE DERIVATIVE; BENZOCAINE; BENZOFURAN DERIVATIVE; CARBAMAZEPINE; CARBANILIC ACID DERIVATIVE; ESLICARBAZEPINE ACETATE; HARKOSERIDE; LAMOTRIGINE; LIDOCAINE; MEXILETINE; OXCARBAZEPINE; OXINDOLE; PHENYTOIN; PIPERIDINE DERIVATIVE; PLACEBO; PYRIMIDINONE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RALFINAMIDE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TECTIN; TETRACAINE; TETRODIN; TOCAINIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT; XENON;

CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; HUMAN; IC 50; NERVE EXCITABILITY; NEUROPATHIC PAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SODIUM TRANSPORT; STRUCTURE ACTIVITY RELATION; TRIGEMINUS NEURALGIA;

EID: 66449112479     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788317883     Document Type: Review

References (146)

1. Julius, D.; Basbaum, A. I. Molecular mechanisms of nociception. Nature 2001, 413, 203-210.
2. Stucky, C. L.; Gold, M. S.; Zhang, X. Mechanisms of pain. Proc. Natl. Acad. Sci. U.SA 2001, 98, 11845-11846.
3. Scholz, J.; Woolf, C. J. Can we conquer pain? Nat. Neurosci. 2002, 5, 1062-1067.
4. Woolf, C. J.; Mannion, R. J. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999, 353, 1959- 1964.
5. Lawson, S. N. Phenotype and function of somatic primary afferent nociceptive neurones with C-, Aδ-, or Aα/β-fibres. Exp. Physiol. 2002, 87, 239-244.
6. Lai, J.; Porreca, F.; Hunter, J. C.; Gold, M. S. Voltage-gated sodium channels and hyperalgesia. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 371-397.
7. Waxman, S. G.; Cummins, T. R.; Dib-Hajj, S.; Fjell, J.; Black, J. A. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve 1999, 22, 1177-1187.
8. Termin, A.; Martinborough, E.; Wilson, D. Recent advances in voltage-gated sodium channel blockers: Therapeutic potential as drug targets in the CNS. Annu. Rep. Med. Chem. 2008, 43, 44-60.
9. Priest, B. On the process of finding novel and selective sodium channel blockers for the treatment of diseases. Top. Med. Chem. 2008, 3, 121-143.
10. + channels: potential for β subunits as therapeutic targets. Expert Opin. Ther. Targets 2008, 12, 1191-1203.
11. Bölcskei, H.; Tarnawa, I.; Kocsis, P. Voltage-gated sodium channel blockers, 2001-2006: An overview. Med. Chem. Res. 2008, 17, 356-368.
12. Childers, W. E.; Gilbert, A. M.; Kennedy, J. D.; Whiteside, G. T. Advances in the development of novel analgesics. Expert Opin. Ther. Pat. 2008, 18, 1027-1067.
13. Kyle, D. J.; Ilyin, V. I. Sodium channel blockers. J. Med. Chem. 2007, 50, 2583-2588.
14. + channels in neuropathic pain. Expert Opin. Invest. Drugs 2007, 16, 635-646.
15. Cummins, T. R.; Rush, A. M. Voltage-gated sodium channel blockers for the treatment of neuropathic pain. Expert Rev. Neurother. 2007, 7, 1597-1612.
16. Tarnawa, I.; Bölcskei, H.; Kocsis, P. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. Recent Pat. CNS Drug Discov. 2007, 2, 57-78.
17. Marron, B. Novel sodium channel blockers for the treatment of neuropathic pain. Annu. Rep. Med. Chem. 2006, 41, 59-73.
18. v1.8 channel blockade as an approach to the treatment of neuropathic pain. Drugs Future 2006, 31, 597-601.
19. Brimble, M. A.; Levi, M. S. A review of agents patented for their neuroprotective properties. Recent Pat. CNS Drug Discov. 2006, 1, 139-146.
20. Roselli, F.; Livrea, P.; Jirillo, E. Voltage-gated sodium channel blockers as immunomodulators. Recent Pat. CNS Drug Discovery 2006, 1, 83-91.
21. Gonzalez, J. E.; Termin, A. P.; Wilson, D. M. Small molecule blockers of voltage-gated sodium channels. In Voltage-Gated Ion Channels as Drug Targets (Methods and Principles in Medicinal Chemistry), Triggle, D. J.; Gopalakrishnan, M.; Rampe, D.; Zheng, W.; Mannhold, R.; Kubinyi, H.; Folkers, G., Eds. Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006, 29, 168-192.
22. Wood, J. N.; Boorman, J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr. Top. Med. Chem. 2005, 5, 529-537.
23. Gribkoff, V. K.; Winquist, R. J. Modulators of peripheral voltage-gated sodium channels for the treatment of neuropathic pain. Expert Opin. Ther. Pat. 2005, 15, 1751-1762.
24. Anger, T.; Madge, D. J.; Mulla, M.; Riddall, D. Medicinal Chemistry of Neuronal Voltage-Gated Sodium Channel Blockers. J. Med. Chem. 2001, 44, 115-137.
25. Madge, D. J. Sodium channels: Recent developments and therapeutic potential. Annu. Rep. Med. Chem. 1998, 33, 51-60.
26. Goldin, A. L.; Barchi, R. L.; Caldwell, J. H.; Hofmann, F.; Howe, J. R. Nomenclature of voltage-gated sodium channels. Neuron 2000, 28, 365-368.
27. Catterall, W. A. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron 2000, 26, 13-25.
28. Qu, Y.; Rogers, J. C.; Chen, S.-F.; McCormick, K. A.; Scheuer, T. Functional roles of the extracellular segments of the sodium channel a subunit in voltage-dependent gating and modulation by β1 subunits. J. Biol. Chem. 1999, 274, 32647-32654.
29. v1.5 by β1- and β3-subunit co-expression in mammalian cells. Pflugers Arch. 2005, 449, 403-412.
30. Catterall, W. A.; Goldin, A. L.; Waxman, S. G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57, 397-409.
31. + channels: Multiplicity of expression, plasticity, functional implications and pathophysiological aspects. Eur. Biophys. J. 2004, 33, 180-193.
32. Hunter, J. C.; Loughhead, D. Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs 1999, 1, 72-81.
33. Krafte, D. S.; Bannon, A. W. Sodium channels and nociception: Recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol. 2008, 8, 50-56.
34. Kalso, E. Sodium channel blockers in neuropathic pain. Curr. Pharm. Des. 2005, 11, 3005-3011.
35. Finnerup, N. B.; Sindrup, S. H.; Bach, F. W.; Johannesen, I. L.; Jensen, T. S. Lamotrigine in spinal cord injury pain: A randomized controlled trial. Pain 2002, 96, 375-383.
36. Mao, J.; Chen, L. L. Systemic lidocaine for neuropathic pain relief. Pain 2000, 87, 7-17.
37. Petersen, K. L.; Maloney, A.; Hoke, F.; Dahl, J. B.; Rowbotham, M. C. A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. J. Pain 2003, 4, 400-406.
38. Yogeeswari, P.; Ragavendran, J. V.; Thirumurugan, R.; Saxena, A.; Sriram, D. Ion channels as important targets for antiepileptic drug design. Curr. Drug Targets 2004, 5, 589-602.
39. v1.3 antisense after spinal cord injury. J. Neurophysiol. 2006, 95, 3343-3352.
40. v1.3 expression and neuropathic pain behavior in rats. Pain 2005, 117, 145-153.
41. v1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. USA 2004, 101, 12706-12711.
42. v1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 2004, 24, 8232-8236.
43. Cox, J. J.; Reimann, F.; Nicholas, A. K.; Thornton, G.; Roberts, E. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444, 894-898.
44. Lai, J.; Gold, M. S.; Kim, C.-S.; Bian, D.; Ossipov, M. H. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Nav1.8. Pain 2002, 95, 143- 52.
45. Gold, M. S.; Weinreich, D.; Kim, C.-S.; Wang, R.; Treanor, J. Redistribution of Nav1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 2003, 23, 158-166.
46. Priest, B. T.; Murphy, B. A.; Lindia, J. A.; Diaz, C.; Abbadie, C. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc. Natl. Acad. Sci. USA 2005, 102, 9382-9387.
47. Smith, E. S. J.; Momin, A. Persistent pain: The contribution of Nav1.9. J. Physiol. 2008, 586, 2249-2250.
48. Birch, P. J.; Dekker, L. V.; James, I. F.; Southan, A.; Cronk, D. Strategies to identify ion channel modulators: Current and novel approaches to target neuropathic pain. Drug Discov. Today 2004, 9, 410-418.
49. Fitch, R. W.; Daly, J. W. Phosphorimaging detection and quantitation for isotopic ion flux assays. Anal. Biochem. 2005, 342, 260-270.
50. Trivedi, S.; Dekermendjian, K.; Julien, R.; Huang, J.; Lund, P.-E. Cellular HTS assays for pharmacological characterization of Nav1.7 modulators. Assay Drug Dev. Technol. 2008, 6, 167-179.
51. Attal, N.; Bouhassira, D. Translating basic research on sodium channels in human neuropathic pain. J. Pain 2006, 7, S31-S37.
52. + channel blockers in two rat models of neuropathic pain. Eur. J. Pharmacol. 2003, 458, 275-282.
53. Backonja, M. M. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002, 59, S14-S17.
54. Tremont-Lukats, I. W.; Megeff, C.; Backonja, M. M. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000, 60, 1029-1052.
55. Backonja, M. M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin. J. Pain 2000, 16, S67-S72.
56. Clare, J. J.; Tate, S. N.; Nobbs, M.; Romanos, M. A. Voltage-gated sodium channels as therapeutic targets. Drug Discov. Today 2000, 5, 506-520.
57. + currents in rat sensory neurons and recombinant Nav1.2 channels. Neurosci. Lett. 2006, 395, 179-184.
58. Gerner, P.; Binshtok, A. M.; Wang, C.-F.; Hevelone, N. D.; Bean, B. P.; Woolf, C. J.; Wang, G. K. Capsaicin combined with local anesthetics preferentially prolongs sensory/nociceptive block in rat sciatic nerve. Anesthesiology 2008, 109, 872-878.
59. + channel expressed in a stable mammalian cell line. Pflugers Arch. 2001, 441, 425-433.
60. Lees, G.; Leach, M. J. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res. 1993, 612, 190-199
61. Vinik, A. I.; Tuchman, M.; Safirstein, B.; Corder, C.; Kirby, L.; Wilks, K.; Quessy, S.; Blum, D.; Grainger, J.; White, J.; Silver, M. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebocontrolled studies. Pain 2007, 128, 169-179.
62. Rao, R. D.; Flynn, P. J.; Sloan, J. A.; Wong, G. Y.; Novotny, P.; Johnson, D. B.; Gross, H. M.; Renno, S. I.; Nashawaty, M.; Loprinzi, C. L. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008, 112, 2802-2808.
63. Attal, N.; Cruccu, G.; Haanpaa, M.; Hansson, P.; Jensen, T. S.; Nurmikko, T.; Sampaio, C.; Sindrup, S.; Wiffen, P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 2006, 13, 1153-1169.
64. Sindrup, S. H.; Jensen, T. S. Pharmacotherapy of trigeminal neuralgia. Clin. J. Pain 2002, 18, 22-27.
65. Finnerup, N. B.; Otto, M.; McQuay, H. J.; Jensen, T. S.; Sindrup, S. H. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005, 118, 289-305.
66. Ambrosio, A. F.; Soares-Da-Silva, P.; Carvalho, C. M.; Carvalho, A. P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 2002, 27, 121-130.
67. Perucca, E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2006, 61, 246-255
68. Carrazana, E.; Mikoshiba, I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J. Pain Symptom Manage. 2003, 25, S31-S35.
69. Beydoun, A.; Shaibani, A.; Hopwood, M.; Wan, Y. Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study. Acta Neurol. Scand. 2006, 113, 395-404.
70. Solaro, C.; Restivo, D.; Mancardi, G. L.; Tanganelli, P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: A pilot study. Neurol. Sci. 2007, 28, 156-158.
71. Czapinski, P.; Blaszczyk, B.; Czuczwar, S. J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 3-14.
72. Raskin, P.; Donofrio, P. D.; Rosenthal, N. R.; Hewitt, D. J.; Jordan, D. M. Topiramate vs placebo in painful diabetic neuropathy. Neurology 2004, 63, 865-873.
73. Chong, M. S.; Libretto Susan, E. The rationale and use of topiramate for treating neuropathic pain. Clin. J. Pain 2003, 19, 59-68.
74. Strichartz, G. R.; Zhou, Z.; Sinnott, C.; Khodorova, A. Therapeutic concentrations of local anesthetics unveil the potential role of sodium channels in neuropathic pain. Novartis Found. Symp. 2002, 241, 189-205.
75. + currents in rat sensory neurons. Anesthesiology 2001, 94, 137-144.
76. All non-referenced clinical studies were identified using the Thomson Pharma and an IDdb3 (Thomson Pharma Partnering) databases, © 2009, Thomson Reuters.
77. + channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. Exp. Neurol. 2007, 208, 63-72.
78. + currents in dorsal root ganglion neurons. Eur. J. Pharmacol. 2005, 510, 197-208
79. Zhang, S.-H.; Blech-Hermoni, Y.; Faravelli, L.; Seltzer, Z. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain 2008, 139, 293-305.
80. + channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain 2003, 102, 17-25.
81. Errington, A. C.; Stohr, T.; Heers, C.; Lees, G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73, 157-169.
82. Rauck, R. L.; Shaibani, A.; Biton, V.; Simpson, J.; Koch, B. Lacosamide in painful diabetic peripheral neuropathy: A phase 2 double-blind placebo-controlled study. Clin. J. Pain 2007, 23, 150-158.
83. Hagen, N. A.; Fisher, K. M.; Lapointe, B.; du Souich, P.; Chary, S.; Moulin, D.; Sellers, E.; Ngoc, A.H. An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. J. Pain Symptom Manage. 2007, 34, 171-182.
84. Dong, Q.; Shum, F. H. A method of analgesia using sodium channel blockers. PCT Int. Appl. WO2002/022129, 2002.
85. Ku, B.; Shum, F. H. K. Analgesic composition and method. PCT Int. Appl. WO02094272, 2002.
86. Hagen, N. A.; du Souich, P.; Lapointe, B.; Ong-Lam, M.; Dubuc, B. Tetrodotoxin for moderate to severe cancer pain: A randomized, double blind, parallel design multicenter study. J. Pain Symptom Manage. 2008, 35, 420-429.
87. Hall, R. L.; Cole, P. J. Amidino compounds for treatment of respiratory disease. PCT Int. Appl. WO2008090366, 2008.
88. Lee, G. Y.; Lee, S. G.; Yoon, S. J.; Lee, B. H.; Oh, G. S. Oxazole-4-carbonylguanidine derivative and its formulation for myocardial ischemia therapy. PCT Int. Appl. KR2008030146, 2008.
89. Mall, M. Use of sodium channel blockers for an early therapy of obstructive lung diseases. PCT Int. Appl. WO2008083942, 2008.
90. Morishita, K.; Takamura, M. Optically active hydroxyquinazolinone derivative, drugs containing them, and their uses. PCT Int. Appl. JP2008115118, 2008.
91. Johnson, M. R. Preparation of pyrazinoylguanidines as sodium channel blockers with b-agonist activity. PCT Int. Appl. WO2007146867, 2007.
92. Johnson, M. R. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing β agonist activity. PCT Int. Appl. WO2007146870, 2007.
93. Johnson, M. R.; Hirsh, A. J.; Boucher, R. C.; Zhang, J. Preparation of phenylpyrazinoylguanidines as sodium channel blockers possessing β-agonist activity. PCT Int. Appl. WO2007146869, 2007.
94. Johnson, M. R.; Molino, B. F.; Sargent, B.; Zhang, J. Preparation of new capped pyrazinoylguanidine-containing amino acid derivatives as sodium channel blockers. U. S. Patent Appl. US2007032509, 2007.
95. Buschmann, H. H.; Hernandez, J. M. V.; Screibmayer, W. Use of 4,9-anhydrotetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel α subunit Nav1.6. PCT Int. Appl. WO2007110220, 2007.
96. Liberatore, A.-M.; Schulz, J.; Favre-Guilmard, C.; Pommier, J.; Lannoy, J.; Pawlowski, E.; Barthelemy, M.-A.; Huchet, M.; Auguet, M.; Chabrier, P.-E.; Bigg, D. Butyl 2-(4-[1.1'-biphenyl]-4- yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain. Bioorg. Med. Chem. Lett. 2007, 17, 1746-1749.
97. Liberatore, A.-M.; Schulz, J.; Pommier, J.; Barthelemy, M.-A.; Huchet, M.; Chabrier, P.-E.; Bigg, D. 2-Alkyl-4-arylimidazoles: Structurally novel sodium channel modulators. Bioorg. Med. Chem. Lett. 2004, 14, 3521-3523.
98. Rivara, M.; Baheti, A. R.; Fantini, M.; Cocconcelli, G.; Ghiron, C.; Kalmar, C. L.; Singh, N.; Merrick, E. C.; Patel, M. K.; Zuliani, V. 2,4(5)-Diarylimidazoles: Synthesis and biological evaluation of a new class of sodium channel blockers against hNav1.2. Bioorg. Med. Chem. Lett. 2008, 18, 5460-5462.
99. London, C.; Hoyt, S. B.; Parsons, W. H.; Williams, B. S.; Warren, V. A.; Tschirret-Guth, R.; Smith, M. M.; Priest, B. T.; McGowan, E.; Martin, W. J.; Lyons, K. A.; Li, X.; Karanam, B. V.; Jochnowitz, N.; Garcia, M. L.; Felix, J. P.; Dean, B.; Abbadie, C.; Kaczorowski, G. J.; Duffy, J. L. Imidazopyridines: A novel class of hNav1.7 channel blockers. Bioorg. Med. Chem. Lett. 2008, 18, 1696-1701.
100. Hoyt, S. B.; London, C.; Gorin, D.; Wyvratt, M. J.; Fisher, M. H.; Abbadie, C.; Felix, J. P.; Garcia, M. L.; Li, X.; Lyons, K. A.; McGowan, E.; MacIntyre, D. E.; Martin, W. J.; Priest, B. T.; Ritter, A.; Smith, M. M.; Warren, V. A.; Williams, B. S.; Kaczorowski, G. J.; Parsons, W. H. Discovery of a novel class of benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 2007, 17, 4630-4634.
101. Hoyt, S. B.; London, C.; Ok, H.; Gonzalez, E.; Duffy, J. L.; Abbadie, C.; Dean, B.; Felix, J. P.; Garcia, M. L.; Jochnowitz, N.; Karanam, B. V.; Li, X.; Lyons, K. A.; McGowan, E.; MacIntyre, D. E.; Martin, W. J.; Priest, B. T.; Smith, M. M.; Tschirret-Guth, R.; Warren, V. A.; Williams, B. S.; Kaczorowski, G. J.; Parsons, W. H. Benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 2007, 17, 6172-6177.
102. Liu, S.; Fraser, R.; Fu, J.; Kamboj, R. Methods of using benzodioxine compounds in treating sodium channel-mediated diseases or conditions. PCT Int. Appl. WO2008106633, 2008.
103. Chowdhury, S.; Fraser, R.; Fu, J.; Kamboj, R. Preparation of thiazole, oxazole and imidazole compounds for treating sodium channel-mediated diseases or conditions. PCT Int. Appl. WO2008101029, 2008.
104. Liu, S.; Fu, J.; Kamboj, R.; Jia, Q.; Wood, M.; Chowdhury, S.; Sun, J. Preparation of pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions. PCT Int. Appl. WO2008097991, 2008.
105. Liu, S.; Sun, J.; Fraser, R.; Fu, J.; Kamboj, R.; Hou, D.; Sviridov, S. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions and their preparation. PCT Int. Appl. WO2008094909, 2008.
106. Kamboj, R.; Fraser, R.; Fu, J.; Kodumuru, V.; Sadalapure, K. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions. PCT Int. Appl. WO2008121859, 2008.
107. Cadieux, J.-J.; Chowdhury, S.; Fu, J.; Kamboj, R.; Hsieh, T.; Jia, Q.; Liu, S.; Sun, J. Preparation of spiro[furo[3,2-c]pyridine-3,3′-ndol]-2(1H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain. PCT Int. Appl. WO2008046049, 2008.
108. Chafeev, M.; Chowdhury, S.; Fraser, R.; Fu, J.; Kamboj, R.; Hou, D.; Liu, S.; Bagherzadeh, M. S.; Sviridov, S.; Sun, S.; Sun, J.; Chakka, N.; Hsieh, T.; Raina, V. Spiro-oxindole compounds and their preparation, pharmaceutical compositions and use as sodium channel blockers. PCT Int. Appl. WO2006110917, 2006.
109. Chafeev, M.; Chowdhury, S.; Fraser, R.; Fu, J.; Kamboj, R.; Hou, D.; Liu, S.; Seid Bagherzadeh, M.; Sviridov, S.; Sun, S.; Sun, J.; Chakka, N.; Hsieh, T.; Raina, V. Preparation of spiro-oxindole compounds as therapeutic agents. PCT Int. Appl. WO2008060789, 2008.
110. Chafeev, M.; Chowdhury, S.; Fraser, R.; Fu, J.; Kamboj, R.; Sviridov, S.; Bagherzadeh, M. S.; Liu, S.; Sun, J. Spiroheterocyclic compounds and their preparation, pharmaceutical compositions and use as sodium channel blocker. PCT Int. Appl. WO2006110654, 2006.
111. Chafeev, M.; Chowdhury, S.; Fu, J.; Kamboj, R. Preparation of tricyclic spiro-oxindole derivatives use as therapeutic agents. PCT Int. Appl. WO2008046046, 2008.
112. Chafeev, M.; Chowdhury, S.; Fu, J.; Kamboj, R.; Hou, D.; Liu, S. Preparation of spiro-heterocyclic derivatives use as therapeutic agents. PCT Int. Appl. WO2008046084, 2008.
113. Chowdhury, S.; Fu, J.; Kamboj, R.; Liu, S.; Jia, Q.; Raina, V.; Sun, J. Preparation of spiro compounds for treatment of sodium channel mediated disease. PCT Int. Appl. WO2008046087, 2008.
114. Chafeev, M.; Chowdhury, S.; Fraser, R.; Fu, J.; Hou, D.; Kamboj, R.; Liu, S.; Sun, S.; Sun, J.; Sviridov, S.; Bagherzadeh, M. S.; Chakka, N.; Hsieh, T.; Raina, V. Preparation of oxindoles for treatment of sodium channel mediated diseases. PCT Int. Appl. WO2006113864, 2006.
115. Chafeev, M.; Chowdhury, S.; Fraser, R.; Fu, J.; Kamboj, R.; Liu, S.; Seid Bagherzadeh, M.; Sviridov, S.; Sun, J. Spiroheterocyclic compounds as therapeutic agents and their preparation, pharmaceutical compositions and use in the treatment of diseases. PCT Int. Appl. WO2008046065, 2008.
116. Reddy, N. L.; Fan, W.; Magar, S. S.; Perlman, M. E.; Yost, E.; Zhang, L.; Berlove, D.; Fischer, J. B.; Burke-Howie, K.; Wolcott, T.; Durant, G. J. Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J. Med. Chem. 1998, 41, 3298-3302.
117. + channel α subunits in a somatic cell line. Neuron 1992, 8, 59-70.
118. Chafeev, M.; Chakka, N.; Chowdhury, S.; Fraser, R.; Fu, J.; Hou, D.; Hsieh, T.; Kamboj, R.; Liu, S.; Raina, V.; Seid Bagherzadeh, M.; Sun, J.; Sun, S.; Sviridov, S. Preparation of oxindoles and their use as sodium channel blockers for treating hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. PCT Int. Appl. WO2008046083, 2008.
119. Marron, B. E.; Fritch, P. C.; Markworth, C. J.; Maynard, A. T.; Swain, N. A. Inhibitors of ion channels. PCT Int. Appl. WO2008118758, 2008.
120. Wang, X.; Fulp, A.; Marron, B.; Beaudoin, S.; Seconi, D.; Suto, M. Aryl sulfonamide compound sodium channel inhibitors, and their therapeutic use. PCT Int. Appl. WO2007056099, 2007.
121. Gonzales, J. E., III; Termin, A. P.; Martinborough, E.; Zimmerman, N. Preparation of N-(4-sulfamoylphenyl) amides as inhibitors of voltage-gated sodium channels. PCT Int. Appl. WO2005013914, 2005.
122. Thaler, F.; Napoletano, M.; Sabido-David, C.; Moriggi, E.; Caccia, C.; Faravelli, L.; Restivo, A.; Salvati, P. Preparation of 2-phenylethylamino derivatives as calcium and/or sodium channel modulators for treating various diseases. RCT Int. Appl. WO2007071311, 2007.
123. Alvaro, G.; Andreotti, D.; Bergauer, M.; Giovannini, R.; Marasco, A. Prolinamide derivatives as sodium channel modulators. PCT Int. Appl. WO2007042250, 2007.
124. Alvaro, G.; Bergauer, M.; Giovannini, R.; Profeta, R. Preparation of (fluorobenzyloxyphenyl)prolinamides as sodium channel modulators. PCT Int. Appl. WO2007042239, 2007.
125. Alvaro, G.; Amantini, D.; Bergauer, M.; Bonetti, F.; Profeta, R. Preparation of a-aminocarboxamides, especially phenylprolinamide and (pyridin-2-yl)prolinamide derivatives, as sodium channel modulators. PCT Int. Appl. WO2007042240, 2007.
126. Alvaro, G.; Large, C. Pharmaceutical compositions comprising 3,5-diamino-6-(2,3- dichlorophenyl)-1,2,4-triazine or R-(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-(fluoromethyl) pyrimidine and an NK1 antagonist. PCT Int. Appl. WO2008090117, 2008.
127. Alvaro, G.; Large, C. Pharmaceutical compositions comprising prolinamide derivatives and [2-methoxy-5-[5-(trifluoromethyl) tetrazol-1-yl]benzyl](2S-phenylpiperidin-3S-yl)amine. PCT Int. Appl. WO2008090114, 2008.
128. Johnson, C. N.; Macpherson, D. T.; Trani, G. Preparation of pyridine amino acid derivatives as sodium channel blockers. PCT Int. Appl. WO2008017691, 2008.
129. Hamlyn, R.; Huckstep, M.; Earnshaw, C. G.; Stokes, S.; Tickle, D.; Allart, B.; Boyd, J. W.; Knutsen, L. J. S.; Lynch, R.; Patient, L. Azacyclic compounds as inhibitors of sensory neuron specific channels (SNS). PCT Int. Appl. WO2006082354, 2006.
130. Besidski, Y.; Gravenfors, Y.; Kers, I.; Skogholm, K.; Svensson, M. Preparation of 3-oxoindole-1-carboxamides as analgesic agents. PCT Int. Appl. WO2008008020, 2008.
131. Soares da Silva, P. Use of 5H-dibenz[b,f]azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders. PCT Int. Appl. WO2007/094694, 2007.
132. Benes, J.; Parada, A.; Figueiredo, A. A.; Alves, P. C.; Freitas, A. P.; Learmonth, D. A.; Cunha, R. A.; Garrett, J.; Soares-da-Silva, P. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz [b,f]azepine-5-carboxamide derivatives. J. Med. Chem. 1999, 42, 2582-2587.
133. Gibson, K. R.; Glossop, M. S. Preparation of aminopyridinamides as sodium channel modulators. PCT Int. Appl. WO2007083239, 2007.
134. Leach, M.; Harbige, L.; Riddall, D.; Barraclough, P. Preparation of triazine derivatives as sodium channel blockers and antifolates for treating neurological disorders, cancer, and malaria. PCT Int. Appl. WO2008007149, 2008.
135. Catalano, A.; Carocci, A.; Corbo, F.; Franchini, C.; Muraglia, M.; Scilimati, A.; De Bellis, M.; De Luca, A.; Camerino, D. C.; Sinicropi, M. S.; Tortorella, V. Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents. Eur. J. Med. Chem. 2008, 43, 2535-2540.
136. De Luca, A.; Talon, S.; De Bellis, M.; Desaphy, J.-F.; Lentini, G.; Corbo, F.; Scilimati, A.; Franchini, C.; Tortorella, V.; Camerino, D. C. Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol. Pharmacol. 2003, 64, 932-945.
137. + channels with increased potency and improved use-dependent activity. J. Med. Chem. 2000, 43, 3792-3798.
138. Muraglia, M.; Franchini, C.; Corbo, F.; Scilimati, A.; Sinicropi, M. S.; De Luca, A.; De Bellis, M.; Camerino, D. C.; Tortorella, V. Synthesis of beta-proline like derivatives and their evaluation as sodium channel blockers. J. Heterocycl. Chem. 2007, 44, 1099-1103.
139. v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat Proc. Natl. Acad. Sci. USA 2007, 104, 8520-8525.
140. v1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem. 2008, 51, 407-416.
141. v1.8 (PN3) sodium channel. MEDI-319, 233rd ACS National Meeting, Chicago, IL, 2007.
142. v1.8 (PN3) sodium channel MEDI-321, 233rd ACS National Meeting, Chicago, IL, 2007.
143. Drizin, I.; Gregg, R. J.; Scanio, M. J. C.; Shi, L.; Gross, M. F.; Atkinson, R. A.; Thomas, J. B.; Johnson, M. S.; Carroll, W. A.; Marron, B. E.; Chapman, M. L.; Liu, D.; Krambis, M. J.; Shieh, C. C.; Zhang, X. F.; Hernandez, G.; Gauvin, D. M.; Mikusa, J. P.; Zhu, C. Z.; Joshi, S.; Honore, P.; Marsh, K. C.; Roeloffs, R.; Werness, S.; Krafte, D. S.; Jarvis, M. F.; Faltynek, C. R.; Kort, M. E. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem. 2008, 16, 6379-6386.
144. v1.4 sodium channels by trifluoperazine involves the local anesthetic receptor. J. Neurophysiol. 2006, 96, 1848-1859
145. v1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol. Pharmacol. 2008, 73, 940-948.
146. + channels. Mol. Pharmacol. 2004, 66, 1652-1661.